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 Inflammatory critical illness is a syndrome that is characterized by acute inflammation and organ injury, and it
is triggered by infections and noninfectious tissue injury, both of which activate innate immune receptors and
pathways. Although reports suggest an anti-inflammatory role for the mitogen-activated protein kinase
(MAPK) extracellular signal–regulated kinase 5 (ERK5), we previously found that ERK5 mediates proinflam-
matory responses inprimaryhumancells in response tostimulationofToll-like receptor2 (TLR2).We inhibited
the kinase activities and reduced the abundances of ERK5 and MEK5, a MAPK kinase directly upstream of
ERK5, in primary human vascular endothelial cells andmonocytes, and found that ERK5promoted inflamma-
tion induced by a broad range of microbial TLR agonists and by the proinflammatory cytokines interleukin-
1b (IL-1b) and tumor necrosis factor–a (TNF-a). Furthermore, we found that inhibitors of MEK5 or ERK5
reduced the plasma concentrations of proinflammatory cytokines in mice challenged with TLR ligands or
heat-killed Staphylococcus aureus, as well as in mice that underwent sterile lung ischemia-reperfusion in-
jury. Finally,we found that inhibitionofERK5protectedendotoxemicmice fromdeath. Together, our studies
support a proinflammatory role for ERK5 in primary human endothelial cells and monocytes, and suggest
that ERK5 is a potential therapeutic target in diverse disorders that cause inflammatory critical illness. htt o
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Acute inflammation and organ injury are caused by diverse conditions,
including trauma, hemorrhage, vascular occlusion, transplantation, cardiac
arrest, and sepsis. These bodily insults activate the innate immune system,
which initiates a well-coordinated series of events that have evolved to con-
tain the microbial threat, eliminate the microbes or damaged tissues, initiate
an appropriate adaptive immune response, and instigate tissue repair (1–5).
After more extreme injury, mechanisms designed to limit inflammation and
to restore immune homeostasis become overwhelmed and dysregulated,
leading to uncontrolled systemic inflammation with resultant organ injury,
organ failure, and even death (6, 7). Coagulopathy, a disorder character-
ized by impaired clotting of blood that can cause pathologic microvascular
thrombosis, and vascular leak are believed to potentiate inflammatory or-
gan injury through effects on nutrient and oxygen delivery, tissue edema,
and through secondary ischemia-reperfusion (IR) injury (2, 8–12). Indeed,
multiple organ failure is a leading cause of death of patients hospitalized
with sepsis or traumatic injuries (13–16).
Vascular endothelial cells (ECs) and leukocytes mediate critical aspects
of the innate immune response to infection and injury (1, 17). Receptors
on these cells engage invariant microbial pathogen–associated molecular
patterns (PAMPs) and host-derived, danger-associated molecular patterns
(DAMPs), and, in conjunction with the complement system, they initiate
an acute inflammatory response that is enforced by the immediate release
of proinflammatory mediators, such as interleukin-1b (IL-1b) and tumor
necrosis factor–a (TNF-a) (18–23). Activated leukocytes and ECs secrete
cytokines and chemokines [for example, IL-6, IL-8, CCL2 (also known as
MCP-1), and CCL3 (also known as MIP-1a)] and increase the number of1Department of Anesthesia and Perioperative Care, University of California, San
Francisco, San Francisco, CA 94143, USA. 2Graduate Program in Biomedical
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wwadhesion molecules [for example, E-selectin, P-selectin, vascular cell adhe-
sion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1)]
at their cell surface to facilitate the localization and subsequent diapedesis of
leukocytes, such as neutrophils, to sites of infection and injury (1, 22–25).
Furthermore, factors that induce and perpetuate fibrin deposition and
thrombosis [for example, plasminogen activator inhibitor–1 (PAI-1)] be-
come increased in abundance, whereas those factors [for example, tissue
plasminogen activator (tPA)] that are involved in the breakdown of clots
(fibrinolysis) become decreased in abundance, resulting in the initiation and
persistence of intravascular thrombosis (22, 23, 26, 27). Increased amounts
of PAI-1, which inhibits fibrinolysis, are associated with an increased in-
cidence of organ failure and death in sepsis, pneumonia, and acute lung
injury (ALI) (28). Increased PAI-1 activity likely facilitates the persistence
of microvascular thrombi and impairs blood flow, which may help to
contain invading microbes, as well as promotes vascular permeability
and leukocyte trafficking. During acute inflammatory critical illness, ex-
cessive inflammation, leukocyte recruitment to organs, vascular leak, and
intravascular thrombosis cause organ injury. The failure to shift to a healthy,
proresolving phase of inflammation is in part driven by the sustained en-
gagement of innate immune receptors by PAMPs, DAMPs, and host inflam-
matory mediators (29). Understanding these processes is vitally important in
critical care medicine; however, the biochemical origins and components of
the initial stages of the innate immune response and their role in the devel-
opment of acute inflammatory critical illness are still poorly understood.
Central to all innate immune receptor signaling pathways are the tran-
scription factor nuclear factor kB (NF-kB) and the intracellular mitogen-
activated protein kinases (MAPKs) (30). NF-kB promotes the expression
of genes that encode inflammatory cytokines, whereas the MAPKs primarily
act by modulating gene and protein expression and stability and by regulat-
ing the integrity of protein complexes within the cell (31, 32). The classical
MAPKs p38, c-Jun N-terminal kinase (JNK), extracellular signal–regulated
kinase 1 (ERK1), andERK2are themost thoroughly studied; however, several
other family members exist, including ERK5 [also known as big MAPK
(BMK1) or MAPK7], ERK3/4, ERK7/8, and Nemo-like kinase (NLK)
(31, 33). The classical MAPKs have been considered as therapeutic targetsw.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 1
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 to treat inflammatory disorders for some time, but several clinical trials, par-
ticularly those that used p38a inhibitors, were discontinued as a result of
poor safety profiles or low long-term efficacy (30, 34). The other under-
studied MAPK family members, such as ERK5, may be of interest as ther-
apeutic targets in acute inflammatory critical illness because of their distinct
structures and more restricted roles in cells, which may limit the occurrence
of potential side effects. We reported that ERK5 mediates the Toll-like re-
ceptor 2 (TLR2)–dependent activation of inflammatory responses in human
monocytes and ECs, and that it promotes the TLR2-dependent activity of
PAI-1 in ECs, indicating that other understudied MAPK family members
also function in innate immune signaling pathways (23).
ERK5 and its upstream activator MAP/ERK kinase 5 (MEK5) were in-
dependently described in 1995 (35–37). Compared to other MAPK family
members, ERK5 is substantially larger and has a distinct C-terminal domain,
which contains a proline-rich region, a nuclear localization signal (NLS), and
a transcriptional activation domain (TAD) that is regulated by autophosphoryl-
ation (fig. S1) (38–42). In resting cells, ERK5 is mainly located in the cyto-
plasm, but upon phosphorylation of ERK5, the NLS is exposed, and ERK5
translocates to the nucleus where it stimulates the activity of several tran-
scription factors (43–54). In addition, ERK5 has several cytoplasmic sub-
strates and binding partners, such as other kinases, adaptors, scaffolds, and
junctional proteins (41, 42, 55–60). ERK5 plays an essential role in embry-
onic development and invascular integrity, as highlighted in studies of global
and EC-specific ERK5 knockout mice (61–65). However, the ablation of
ERK5 inother cells, includingTcells andneuronal cells, is not lethal, although
neuronal deletion affects aspects of neurogenesis and impairs pheromone-
mediated behaviors (66–71). ERK5 and MEK5 are also implicated in solid
tumors and hematologic malignancies, and inhibitors of ERK5 and MEK5
are being explored as potential cancer therapies (1, 72–77). Specifically, over-
expression and constitutive activation of ERK5 andMEK5have been noted in
different tumor cells, and they are reported to correlate with more aggressive
cancer behaviors, development of metastases, chemoresistance, and tumor-
associated angiogenesis (77–88). In contrast, the role of ERK5 in inflamma-
tion ismore controversial. Some studies suggest that ERK5 is anti-inflammatory
(44, 45, 47, 89–92), whereas other studies, including our own, have reported
a proinflammatory role for ERK5 in various cell types (23, 93–99).
Here, we expand on our previously reported observation that ERK5
contributes to proinflammatory signaling downstream of TLR2 (23), test-
ing the hypothesis that ERK5 mediates acute inflammation induced by
microbial ligands as well as by endogenous host factors. In experiments
with cultured primary human ECs and monocytes, we showed that ERK5
promoted inflammation downstream of diverse inflammatory mediators
in vitro, including fibroblast-stimulating ligand 1 (FSL-1) (a ligand of TLR2
and TLR6), lipopolysaccharide (LPS; a TLR4 agonist), IL-1b, and TNF-a.
In addition, we found that inhibition of ERK5 activity markedly improved
the survival rates of endotoxemic mice and reduced the amounts of circulat-
ing inflammatory mediators in mice treated with the TLR1 and TLR2
agonist Pam3Cys, LPS, or heat-killed Staphylococcus aureus (HKSA), as
well as in mice that underwent sterile lung IR injury. Together, our studies
support a proinflammatory role for ERK5 in primary human ECs and
monocytes, and suggest that ERK5 is a potential therapeutic target in di-
verse disorders that cause inflammatory critical illness.RESULTS
ERK5 activity promotes the secretion of proinflammatory
cytokines by ECs
We previously showed that ERK5 mediates TLR2 signaling in human ECs,
human peripheral blood mononuclear cells (PBMCs), and the monocyticwwcell line THP-1, and that the bacterial lipopeptide TLR1/2 agonist Pam3Cys
stimulates the activation of endogenous ERK5 in human umbilical vein
endothelial cells (HUVECs) (23). To determine whether ERK5 also pro-
moted EC activation downstream of other exogenous (for example, FSL-1
and LPS) and endogenous (for example, TNF-a and IL-1b) inflammatory
mediators, we first analyzed the effects of the ERK5 inhibitors XMD8-92
and XMD17-109 (also known as ERK5-IN-1) on the FSL-1–, LPS-,
TNF-a–, and IL-1b–induced production of IL-6 and IL-8 by human lung
microvascular endothelial cells (HMVEC-lung cells) and HUVECs
(75, 100, 101). We found that both ERK5 inhibitors inhibited the secretion
of both IL-6 and IL-8 from HMVEC-lung cells treated with any of the
inflammatory agonists (Fig. 1, A to H). We also performed a detailed anal-
ysis of the absolute half-maximal inhibitory concentration (IC50) values for
the inhibitory effects of XMD8-92 and XMD17-109 on IL-6 and IL-8 secre-
tion by both HUVECs and HMVEC-lung cells (Tables 1 and 2). These
results suggest that XMD17-109 has a modestly higher efficacy than
XMD8-92 in both HUVECs and HMVEC-lung cells, and that both in-
hibitors had a higher efficacy in HMVEC-lung cells than in HUVECs. Ad-
ditionally, the ERK5 inhibitors more potently inhibited the secretion of IL-6
than that of IL-8. None of the inhibitors substantially affected cell viability
at the concentrations used in our assays as measured by 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay (fig. S2). Fur-
thermore, we found that initiating treatment of HMVEC-lung cells with
XMD8-92 anytime from 2 hours before through to 2 hours after the ad-
dition of LPS reduced the amounts of IL-6 and IL-8 secreted by the cells
(fig. S3, A and B). These data suggests that ERK5 promotes the secretion of
IL-6 and IL-8 by HUVECs and HMVEC-lung cells in response to both
endogenous and exogenous inflammatory mediators.
MEK5 activity in ECs promotes the secretion of
proinflammatory cytokines
The MAPK kinase (MAPKK) MEK5 binds to ERK5 and phosphorylates
its activation loop to induce ERK5 activity (fig. S1) (102). Therefore, we
tested whether the MEK5 inhibitor BIX02189 could reduce the LPS- and
TNF-a–induced secretion of IL-6 and IL-8 by HMVEC-lung cells. In-
deed, we found that BIX02189 substantially reduced the amounts of
IL-6 and IL-8 secreted by ECs (Fig. 1, I and J). As before, we found that
BIX02189 had no substantial effect on cell viability at the concentrations
used in our assays (fig. S2C). This result suggests that the MEK5-ERK5
signaling axis promotes an inflammatory response in human ECs.
ERK5 and MEK5 promote the secretion of
proinflammatory cytokines by ECs
To further confirm the roles of MEK5 and ERK5 in the inflammatory ac-
tivation of HMVEC-lung cells, we used RNA interference (RNAi)–mediated
protein knockdown to reduce the abundance of either ERK5 or MEK5 in
HMVEC-lung cells. The short inhibitory RNAs (siRNAs) specific for
MAPK7 (which encodes ERK5) and MAP2K5 (which encodes MEK5)
substantially reduced the abundances of ERK5 and MEK5, respectively,
but did not affect the abundances of ERK1 and ERK2 or of MEK1 and
MEK2, which have kinase domain sequences most similar to those of
ERK5 and MEK5, respectively (Fig. 2, A to D) (36, 37). Consistent with
the ERK5 inhibitor studies, the specific knockdown of ERK5 reduced the
amounts of both IL-6 and IL-8 that were secreted by HMVEC-lung cells
treated with either LPS or TNF-a (Fig. 2, E and F), again suggesting a role
for ERK5 in inflammatory pathways in ECs. Knockdown of MEK5, how-
ever, reduced the amount of IL-8, but not IL-6, that was secreted by HMVEC-
lung cells in response to either LPS or TNF-a (Fig. 2, G and H). It is possible
that whereas the incomplete knockdown of MEK5 was sufficient to sub-
stantially inhibit IL-8 secretion, the same was not true for IL-6 secretion.w.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 2
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 Table 1. Micromolar IC50 values for XMD8-92 in different ECs.Agonist
HUVECs HMVEC-lungcellsIL-6 IL-8 IL-6 IL-8Pam3Cys
10 mg/ml 1.17 0.91 0.70 0.93FSL-1
10 mg/ml 3.18 4.68 1.70 1.55LPS
10 mg/ml 1.69 3.67 2.77 4.22
1 mg/ml 2.95 2.91 1.92 2.47TNF-a
10 ng/ml 2.01 4.33 0.93 2.96IL-1b
0.1 ng/ml 1.60 3.24 0.95 0.98Average IC50 2.10 3.29 1.50 2.19wwTable 2. Micromolar IC50 values for XMD17-109 in different ECs.
n.d., no data.Agonistw.SCIENCESIGNALINGHUVECs.org 25 August 2015 Vol 8 IHMVEC-lung
cellsIL-6 IL-8 IL-6ssue 391 ra86IL-8Pam3Cys
10 mg/ml 0.38 0.39 0.39 0.45FSL-1
10 mg/ml 2.02 1.83 0.82 0.79LPS
10 mg/ml 0.80 0.74 0.66 1.17
1 mg/ml 1.37 1.88 0.68 0.96TNF-a
10 ng/ml 0.61 2.63 0.43 0.59IL-1b
10 ng/ml 3.46 3.68 n.d. n.d.
1 ng/ml 3.26 1.98 0.58 0.67
0.1 ng/ml 0.58 0.63 0.41 0.48Average IC50 1.56 1.72 0.57 0.73Fig. 1. The kinase activities of ERK5 and MEK5 promote the inflam-
matory activation of ECs in vitro. (A to J) HMVEC-lung cells were
pretreated for 1 hour with vehicle [dimethyl sulfoxide (DMSO)],
5 mM XMD8-92, 1 mM XMD17-109, or 10 mM BIX02189 before
being treated for an additional 6 hours with vehicle (0.9% saline),
LPS (10 mg/ml), TNF-a (100 ng/ml), FSL-1 (10 mg/ml), or IL-1b
(0.1 ng/ml) while in the continuous presence of DMSO or inhibitor.
The concentrations of IL-6 and IL-8 that were secreted by the cells
into the culture medium were determined by enzyme-linked im-
munosorbent assay (ELISA). NS, not significant. *P < 0.05 and
**P < 0.01 when comparing between cells treated with inflamma-
tory stimulus in the presence or absence of inhibitor; #P < 0.05
##and P < 0.01 when comparing between cells treated with vehicle alone and cells treated with inflammatory stimulus in the presence or absence
of inhibitor. Data are means ± SD of four sample wells per group and are representative of three independent experiments.3
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 Fig. 2. ERK5 and MEK5 proteins promote
the inflammatory activation of ECs in vitro.
(A to D) HMVEC-lung cells were trans-
fected with (A and B) MAPK7-specific (to
knockdown ERK5), (C and D) MAP2K5-
specific (to knockdown MEK5), or (A to D)
control siRNAs. Seventy-two hours later,
cell lysates were analyzed by Western
blotting with antibodies specific for the indi-
cated proteins. Western blots were sub-
jected to densitometric analysis. Bar graphs
show the ratio of the abundances of (B)
ERK5 and (D) MEK5 normalized to that of
actin and are expressed relative to those in
untreated control cells. *P < 0.05 when com-
paring relative densities between cells
transfected with kinase-specific siRNA
and those transfected with control siRNA.
Data in (B) and (D) are means ± SD of the
specific protein densitometry values from
four independent Western blotting experi-
ments. (E to H) HMVEC-lung cells trans-
fected with MAPK7-specific, MAP2K5-specific,
or control siRNAs were subsequently treated
with vehicle (0.9% saline), LPS (10 mg/ml),
or TNF-a (100 ng/ml) for 6 hours. The con-
centrations of IL-6 and IL-8 secreted by the
cells into the culture medium were then
determined by ELISA. *P < 0.05 when com-
paring control siRNA–transfected cells
treated with inflammatory stimulus with spe-
cific siRNA–transfected cells treated with
inflammatory stimulus; #P < 0.05 when com-
paring cells treated with vehicle alone with
siRNA-transfected cells treated with in-
flammatory stimulus. Data in (E) to (H) are
means ± SD of four sample wells per group
and are representative of three indepen-
dent experiments.www.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 4
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 Alternatively, an off-target effect of the MAP2K5-specific siRNA may
have compensated for the effect of MEK5 knockdown on IL-6 secretion.
Indeed, we performed an extensive BLAST search to find potential off-
target genes for the siRNAs contained in theMAPK7 siRNAs that we used.
We found that three of the four siRNAs had 13 of their 19 nucleotides
overlap with sequences in MAP2K4 (the gene that encodes MEK4), which
is an upstream MAPKK for p38, JNK1, and JNK2. Thus, the off-target
knockdown of this kinase could potentially result in a compromised inflam-
matory response (103). However, we did not observe a substantial effect on
MEK4 protein abundance in HMVEC-lung cells transfected with
MAPK7-specific siRNA, suggesting that knockdown of MEK4 was
not likely responsible for the observed outcomes (Fig. 2, A and B).
Together, the results of our RNAi-mediated knockdown studies indicate
that the MEK5-ERK5 axis in human ECs promotes the secretion of proin-
flammatory cytokines in response to TLR4 and TNF receptor (TNFR)
signaling.
ERK5 promotes the adhesion of neutrophils to activated
HMVEC-lung cells
To analyze the contribution of ERK5 in ECs to leukocyte adhesion, we
used a neutrophil adhesion assay with primary human neutrophils and
HMVEC-lung cells (104). After a 3-hour treatment of monolayers of
HMVEC-lung cells with FSL-1, LPS, or TNF-a in the presence of either
of the ERK5 inhibitors XMD8-92 or XMD17-109, there was a marked
decrease in the numbers of neutrophils that adhered to the activated
HMVEC-lung cell monolayers compared to those that adhered to mono-
layers of control cells that were treated with proinflammatory mediators in
the absence of ERK5 inhibitors (Fig. 3, A to C). Similar results were ob-
tained from experiments with the MEK5 inhibitor BIX02189, although
this inhibitor had a statistically significant effect on adhesion only in ex-
periments in which the monolayers were treated with LPS or TNF-a (fig.
S4, A and B). These observations are consistent with our previous study
that showed that knockdown of ERK5 in ECs reduces the adherence of
neutrophils to HMVEC-lung cells activated with Pam3Cys (23). These
data suggest that the ERK5 signaling pathway is necessary for maximal
neutrophil adhesion to activated ECs.wwERK5 promotes the secretion of proinflammatory
cytokines from PBMCs and purified monocytes
We previously found that ERK5 is a critical intermediary in the inflamma-
tory activation of PBMCs in response to the stimulation of TLR1 and
TLR2 (23). Here, we assessed the role of ERK5 in inflammatory signalingFig. 3. ERK5 promotes the binding of neutrophils to activated ECs. (A and
B) Confluent monolayers of HMVEC-lung cells grown in 48-well tissue
culture plates were pretreated for 1 hour with vehicle (DMSO), 1 mM XMD17-
109 (A), or 5 mM XMD8-92 (B) before being treated with vehicle (0.9%
saline), FSL-1 (10 mg/ml), LPS (10 mg/ml), or TNF-a (100 ng/ml) for an ad-
ditional 3 hours while in the continuous presence of DMSO or inhibitor.
Calcein AM–labeled neutrophils were added at 3 × 105 to 6 × 105 cells
per well and allowed to adhere for 20 min at 37°C before being washed
with phosphate-buffered saline (PBS) to remove nonadherent cells. Pre-
and postwashing fluorescence was read in a fluorescent plate reader. The
relative numbers of the remaining adherent neutrophils were then calcu-
lated. *P < 0.05 and **P < 0.01 when comparing between cells treated with
inflammatory stimulus in the absence or presence of inhibitor. Data are
means ± SD of four (A) or six (B) sample wells per group and are repre-
sentative of two independent experiments. NAA, neutrophil adhesion as-
say. (C) Representative images of calcein-labeled neutrophils bound to
HMVEC-lung cells in the presence and absence of XMD8-92. Fluorescence
images taken with a fluorescein filter set are shown in the left columns of each
group, whereas translucent light microscopy images of the same field of
reference are shown in the right-hand columns (under ×10 magnification).
Images are representative of two independent experiments.w.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 5
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 in human PBMCs and purified monocytes in response to stimulation with
FSL-1 or LPS. We found that the amounts of IL-6 and IL-8 that were
secreted by either cell population were reduced in the presence of the
ERK5 inhibitor XMD8-92 or XMD17-109 (Fig. 4, A to H). We also
found that the ERK5 inhibitors reduced the amounts of TNF-a secreted
by PBMCs and monocytes in response to LPS, but not FSL-1 (Fig. 4, I to
L); however, FSL-1 stimulated the secretion of a negligible amount of
TNF-a from both PBMCs and monocytes. Note that because monocytes
constitute about 10 to 30% of human PBMCs, these results also suggest
that most of the IL-6 and IL-8 secreted by LPS-treated PBMCs is derived
from monocytes (Fig. 4, compare C with G and D with H) (105). Togeth-
er, these data suggest that the MEK5-ERK5 axis promotes the TLR2- and
TLR4-mediated secretion of cytokines by PBMCs and monocytes in
addition to ECs.
Inhibitors of ERK5 and MEK5 reduce the systemic
concentrations of proinflammatory cytokines and
PAI-1 activity in mice treated with LPS or Pam3Cys
To investigate the contribution of ERK5 to systemic inflammation and
coagulopathy in vivo, we pretreated mice with the ERK5 inhibitor XMD8-92
and then challenged them intravenously with Pam3Cys or LPS. The plas-
ma concentrations of IL-6, CCL2, and CCL3 were determined to assess
the role of ERK5 in systemic inflammation, whereas PAI-1 activity was
chosen as a measure of coagulation because increased amounts of PAI-1,
which inhibits fibrinolysis, are associated with an increased incidence of
organ failure and death in sepsis, pneumonia, and ALI (28). Mice were
also pretreated with the ERK5 inhibitor XMD17-109 and then challenged
intravenously with LPS for comparison. The plasma concentrations of IL-6,
CCL2, and CCL3 and the activity of PAI-1 2 hours after challenge with
either Pam3Cys or LPS were all substantially reduced in mice treated with
ERK5 inhibitors compared to those of control mice treated with vehicle
(Fig. 5, A to L). Twenty-four hours after challenge with LPS, mice treated
with the ERK5 inhibitor XMD8-92 had substantially decreased plasma
PAI-1 activity and reduced concentrations of CCL2, but not IL-6 or CCL3
(fig. S5, A to D). Note that the plasma concentrations of IL-6, CCL2, and
CCL3 and the activity of PAI-1 in vehicle- and inhibitor-treated mice were
much lower 24 hours after challenge with LPS than they were at 2 hours
after challenge.
We next assessed the contribution of MEK5 to LPS-induced inflam-
mation and coagulopathy by pretreating mice with the MEK5 inhibitor
BIX02189 before challenging them intravenously with LPS. Two hours
after challenge, the activity of PAI-1 and the concentrations of IL-6 and
CCL2, but not CCL3, were substantially reduced in BIX02189-treated
mice compared to those in vehicle-treated mice (Fig. 5, M to P). These
data support a role for the MEK5-ERK5 signaling axis in the induction
of acute inflammation and coagulopathy in mice challenged systemically
with bacterial PAMPs. To further test this hypothesis, we pretreated mice
with the ERK5 inhibitor XMD8-92 and then challenged them intrave-
nously with HKSA, which contain multiple PAMPs. We observed that,
as compared with vehicle-treated mice, those mice treated with the ERK5
inhibitor had substantially reduced plasma PAI-1 activity and decreased
concentrations of IL-6 and CCL2, but not CCL3, 2 hours after challenge
with HKSA (Fig. 6, A to D).
Inhibition of ERK5 activity protects mice from
LPS-induced mortality
To test the hypothesis that inhibition of ERK5 activity may improve sur-
vival in inflammatory critical illness, we assessed the effects of ERK5 in-
hibition in an LPS-induced (endotoxemic) mortality model. Mice were
treated with the ERK5 inhibitor XMD8-92 30 min before or 1 hour afterwwbeing challenged with an intraperitoneal injection of LPS [lethal dose
(LD)30 to LD50]. In both instances, the inhibition of ERK5 activity con-
ferred the mice with marked protection from LPS-induced lethality, reducing
the mortality of mice at 72 hours from 50 to 0% in mice pretreated with
the inhibitor and from 29 to 0% in mice treated with the inhibitor after
exposure to LPS (Fig. 7, A and B).
ERK5 promotes the production of proinflammatory
cytokines during lung IR injury in vivo
Although the underlying stimuli of acute inflammatory critical illness dif-
fer considerably, they all lead to variable degrees of IR injury, which re-
sults from reduced blood flow as a result of microvascular thrombosis and
decreased arterial blood pressure (12, 106). Reduced perfusion of tissues
leads to cellular stress and even necrosis, with the release of DAMPs that
exacerbate local and systemic inflammation and promote organ injury and
failure (5, 107). In experiments with a mouse model of ventilated lung IR
injury, we found that IR injury increases the abundance of proinflamma-
tory cytokines and chemokines in the bloodstream and in lung tissue com-
pared to that in mice undergoing a sham surgical procedure (108). To test
the hypothesis that ERK5 mediates inflammation after IR injury in the
lung, we pretreated mice with the ERK5 inhibitor XMD8-92 just before
we temporarily occluded the left pulmonary artery for 30 min, and then we
quantified the plasma concentrations of IL-6 and CCL2 1 hour after re-
perfusion. Similar to our results from experiments with LPS and Pam3Cys,
the plasma concentrations of IL-6 and CCL2 in response to IR injury were
substantially less in mice treated with XMD8-92 than they were in vehicle-
treated mice (Fig. 8, A and B). These results suggest that in the lung sub-
jected to IR injury, and potentially in other areas of reduced blood flow, ERK5
promotes the production of proinflammatory cytokines and chemokines.
DISCUSSION
Here, we expanded on our initial observation that ERK5 promotes in-
flammation downstream of TLR2 in both ECs and monocytes, and we
provided data to suggest that ERK5 promotes acute inflammatory events
in vitro and in vivo (23). We found that ERK5 promoted the release of
proinflammatory cytokines from primary human monocytes and ECs, as
well as the adherence of neutrophils to ECs and the release of PAI-1 from
ECs in response to agonists of TLR2 and TLR4, as well as to IL-1b and
TNF-a. Our data support roles for ERK5 and MEK5 activity in mediating
inflammation and coagulopathy induced by systemic bacterial infection, as
evidenced by the reduced concentrations of inflammatory mediators and the
decrease in PAI-1 activity in ERK5 inhibitor–treated mice that were subse-
quently challenged with Pam3Cys, LPS, or HKSA. Indeed, we showed that
abating ERK5 activity improved the survival of endotoxemic mice. Support-
ing a role for ERK5 in inflammation induced by noninfectious injuries is
our finding that an ERK5 inhibitor reduced the plasma concentrations of
inflammatory mediators in a mouse model of lung IR injury. Together, our
results suggest that ERK5 promotes inflammatory pathways downstream
of innate immune receptors and, critically, that the MEK5-ERK5 axis could
potentially be exploited therapeutically to treat various infectious and non-
infectious disorders that cause critical inflammatory illness.
In contrast with our observations, several studies support an anti-inflammatory
role for ERK5 (44, 45, 47, 91). There are several differences between our
studies and those previously reported. First, we used two different specific
inhibitors of ERK5 activity, XMD8-92 and XMD17-109, to assess the role
of ERK5 in acute inflammation (75, 100, 101). XMD17-109 is a highly
specific inhibitor of ERK5, and the crystal structure of XMD17-109 bound
to the kinase domain of ERK5 has been solved (101). Second, we found
that the MEK5 inhibitor BIX02189 reduced inflammatory responses in vitrow.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 6
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 Fig. 4. ERK5 promotes the inflammatory activation of human PBMCs and into theculturemediumweredeterminedbyELISA. *P<0.05whencomparing
monocytes in vitro. (A to L) PBMCs or monocytes (as indicated) were pre-
treated for 1 hour with vehicle (DMSO), 5 mM XMD8-92, or 1 mM XMD17-109
before being treated with vehicle (0.9% saline), FSL-1 (10 mg/ml), or LPS
(10 mg/ml) for an additional 6 hourswhile in the continuous presence of DMSO
or inhibitor. The concentrations of IL-6, IL-8, and TNF-a secreted by the cellswwbetween cells treated with inflammatory stimulus in the presence or absence
of inhibitor; #P<0.05whencomparingbetweencells treatedwith vehiclealone
and cells treated with inflammatory stimulus in the presence or absence of
inhibitor. Data are means ± SD of four sample wells per group and are repre-
sentative of three independent experiments. ag, attogram; fg, femtogram.w.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 7
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 and in endotoxemic mice; however, in some instances, it was less effective
than were the ERK5 inhibitors. BIX02189 is a more promiscuous inhib-
itor than either of the ERK5 inhibitors used in our studies. For example,
BIX02189 also potently inhibits the kinases Lck, Src, colony-stimulating
factor 1 (CSF-1) receptor, and ribosomal S6 kinase 2/4 (RSK2/4). Thiswwmay account for its reduced efficacy in limiting inflammatory activation
in some of our in vitro and in vivo assays (72). Third, we verified the re-
sults from our in vitro experiments using inhibitors with RNAi-mediated
knockdown of both ERK5 and MEK5 proteins in primary human ECs,
and we analyzed the function of endogenous ERK5 and MEK5 in primaryFig. 5. ERK5 promotes the secretion of inflammatory mediators and en-
hances PAI-1 activity after the systemic challenge of mice with Pam3Cys
or LPS. (A to P) Wild-type mice were treated intraperitoneally with
XMD8-92 (50 mg/kg), XMD17-109 (50 mg/kg), BIX02189 (25 mg/kg),
or vehicle [30% (2-hydroxypropyl)-b-cyclodextrin with or without 5%
DMSO] 30 min before they were injected intravenously with Pam3Cys
(2.5 mg/kg), LPS (10 mg/kg), or vehicle (0.9% saline). The plasma con-centrations of IL-6, CCL2, and CCL3 and the activity of PAI-1 were quan-
tified 2 hours after challenge. *P < 0.05 when comparing Pam3Cys- or
LPS-treated mice in the presence or absence of inhibitor; #P < 0.05
when comparing untreated control mice with mice treated with Pam3Cys
or LPS in the presence or absence of inhibitor. Data are means ± SD of
four mice per group and are representative of two independent
experiments.w.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 8
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 human cells in vitro, bypassing the need for transfection studies. Last, we
found that inhibition of ERK5 reduced systemic inflammation in multiple
in vivo models of acute inflammation, including toxicity models of bacte-
rial sepsis and a model of sterile acute inflammation. We recognize that
competitive inhibitors of the adenosine triphosphate (ATP)–binding sites
of kinase domains will undoubtedly have off-target effects, and we have tried
to extensively address this possibility in our in vitro studies by using in-
hibitors of not only ERK5 but also MEK5 and by complementing these
studies with siRNA-mediated knockdown of endogenous ERK5 andMEK5
in ECs. We observed highly consistent effects on inflammatory outcomes
with each of these methods. Although it is possible that the inhibition of
another protein in addition to ERK5 or MEK5 may have contributed to
the outcomes that we observed, the sum total of our in vitro data suggests
that the effects that we observed in vivo were a result of inhibition of the
MEK5-ERK5 signaling pathway. Together, our results suggest that ERK5
promotes acute inflammation in vitro and in vivo.
We speculate that blood flow conditions may determine whether ERK5
serves a proinflammatory or anti-inflammatory role. Under normal phys-
iologic conditions, blood flow is laminar, whereas sepsis and tissue injury
or distress can cause decreased and nonlaminar blood flow to occur. Per-
haps under laminar blood flow, ERK5 activation protects against vascular
inflammation, whereas under nonlaminar blood flow, ERK5 promotes in-
flammation. Our hypothesis that vascular flow conditions determine wheth-wwer ERK5 serves a proinflammatory or anti-inflammatory role is supported
by our finding that the induction of inflammation by temporarily occlud-
ing blood flow to the mouse lung is dependent on ERK5 activity. Further
support for this differential role of ERK5 comes from a report that shows
that modification of ERK5 with the small ubiquitin-like modifier (SUMO)
promotes inflammatory pathways under conditions of disrupted laminar flow,
which suggests that posttranslational modifications of ERK5 may switch
its function from a protective to a proinflammatory one (90). Therefore, a
potential paradigm for the role of ERK5 in inflammation emerges: under
normal flow conditions in the vasculature, ERK5 may protect against the
inflammatory activation of ECs and therefore maintain endothelial ho-
meostasis and vascular integrity; however, during an infectious or traumatic
insult, when blood flow is compromised, ERK5 may promote the inflam-
matory activation of ECs.
The signaling pathways that lead to the activation of ERK5 down-
stream of the innate immune receptors are not known. With an appropriate
stimulus, MAPKs are activated through a highly conserved sequence of phos-
phorylation events; that is, MAPKK kinases (MAPKKKs) activate MAPKKs,Fig. 7. Inhibition of ERK5 protects mice from endotoxemic mortality. (A and
B) Wild-type mice were treated intraperitoneally with XMD8-92 (50 mg/kg)
or vehicle [30% (2-hydroxypropyl)-b-cyclodextrin] 30 min before (A) or
1 hour after (B) being injected intraperitoneally with LPS [15 mg/kg (A) or
12.5 mg/kg (B)] or vehicle (0.9% saline). The survival of the mice was
monitored for up to 72 hours. Data are from 8 (A) or 14 (B) mice per group
from a single experiment and are representative of two independent
experiments. The concentration of LPS used was chosen to achieve a 30
to 50%mortality rate (LD30 to LD50) in control mice after 72 hours. *P < 0.05
when comparing control mice with inhibitor-treated mice. Mortality data
were analyzed with Kaplan-Meier curves.Fig. 6. ERK5 promotes the secretion of inflammatory mediators and en-
hances PAI-1 activity after the systemic challenge of mice with HKSA. (A to
D) Wild-type mice were treated intraperitoneally with XMD8-92 (50 mg/kg)
or vehicle [30% (2-hydroxypropyl)-b-cyclodextrin] 30 min before being
injected intravenously with HKSA (2.5 × 1010 bacteria/kg) or vehicle
(0.9% saline). The plasma concentrations of IL-6, CCL2, and CCL3 and
the activity of PAI-1 were quantified 2 hours after the mice were challenged.
*P < 0.05 when comparing HKSA-treated mice in the presence or ab-
sence of inhibitor; #P < 0.05 when comparing untreated control mice with
mice treated with HKSA in the presence or absence of inhibitor. Data are
means ± SD of four mice per group and are representative of two in-
dependent experiments.w.SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 9
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 which in turn activate a specific MAPK (30, 33). The MAPKKKs
MAPK/ERK kinase kinase 2 (MEKK2) and MEKK3 are thought to
phosphorylate, and thus activate, MEK5, the only kinase known to acti-
vate ERK5 (35, 38, 39, 109). Tumor progression locus 2 (Tpl2), another
MAPKKK, also activates the MEK5-ERK5 pathway (110). Notably, Tpl2
can promote inflammation by enhancing the formation of active NF-kB
heterodimers (111). There is currently no consensus on whether MEKK2,
MEKK3, or Tpl2 is involved in the activation of ERK5 downstream of
innate immune receptors; indeed, other MAPKKKs, such as transforming
growth factor–b (TGF-b)–activated kinase 1 (TAK1) or apoptosis signal–
regulating kinase 1 (ASK1), may be involved (30).
Within the nucleus, ERK5 stimulates various transcription factors
(43–53, 112–114). In particular, ERK5 stimulates members of the MEF2
family (including MEF2A, MEF2C, and MEF2D) and the AP-1 family
(including c-Jun and c-Fos) of transcription factors (50). For example, the
ERK5-dependent activation of MEF2C and MEF2D induces expression
of the gene encoding c-Jun, and, downstream of Tpl2, ERK5 stimulates the
promoter of the same gene concomitantly with JNK and p38 (53, 110, 115).
Furthermore, ERK5 may increase the abundance and activation of c-Fos
in certain instances (46, 49). These studies all point to a role for ERK5 in
the regulation of AP-1, which is of particular interest because the AP-1 fam-
ily members c-Jun and c-Fos induce the expression of genes whose products
mediate inflammation and cell survival (116–118). ERK5 is thought to
both stimulate and inhibit NF-kB activity. In this regard, ERK5 may de-
crease NF-kB activity by increasing the abundance of the transcription
factor Krüppel-like factor 2 (KLF2) (119, 120). In ECs, an increase in the
amount of KLF2 reduces the abundances of VCAM-1, E-selectin, tissue
factor, and PAI-1, but not ICAM-1, as well as potently inhibits vascular
endothelial growth factor (VEGF)–mediated vascular permeability (121–123).
Furthermore, KLF2 is proposed to have anti-inflammatory properties in
healthy ECs under laminar flow, but not in areas of compromised blood
flow (124–126). In contrast with these findings, ERK5 promotes NF-kB
activity in other cell systems, as well as during the cell cycle (127–129).
In conclusion, we have identified a previously uncharacterized pro-
inflammatory role for ERK5 downstream of multiple innate immune receptors
that engage exogenous and endogenous inflammatory mediators. Fur-
thermore, we found that ERK5 mediated the increased production ofwww.SCIENCESIGNALING.org 25proinflammatory cytokines involved in leu-
kocyte recruitment and activation in mice
exposed to microbial factors or tissue is-
chemia. Placing our findings into the con-
text of the literature, we speculate that
blood flow conditions may determine
whether ERK5 serves a proinflammatory
or anti-inflammatory role. We propose that
under steady-state conditions, ERK5 may
help to maintain vascular integrity and en-
dothelial homeostasis, perhaps in part through
KLF2, but that during sepsis or tissue in-
jury, ERK5 promotes the proinflammatory
activation of ECs, which, if sustained, could
lead to organ injury and failure. Together,
our studies suggest that ERK5, with its
distinct structure and limited role in cells,
may be a potential therapeutic target in
the fight against inflammatory critical ill-
ness, a common and often lethal condition
in humans.MATERIALS AND METHODS
Cells
HUVECs (passages 2 to 6 from multiple donors, Lonza) and HMVEC-
lung cells (passages 4 to 9 from female and male donors, PromoCell)
were incubated at 37°C under humidified 5% CO2. HUVECs and HMVEC-
lung cells were cultured in endothelial growth medium–2 (EGM-2) and
EGM-2 microvascular medium (Lonza), respectively. Human PBMCs
and neutrophils were isolated by gradient centrifugation with Lymphoprep
and Polymorphprep (Axis-Shield), respectively, of heparinized whole
blood collected by venipuncture from healthy human volunteers. PBMCs
were isolated according to the manufacturer’s instructions, whereas neutro-
phils were isolated as described previously (104). Human CD14+ monocytes
were isolated from PBMCs by positive selection with CD14 MicroBeads
and LS columns (Miltenyi Biotec) according to the manufacturer’s
instructions.
Inhibitor and agonist treatments
All ECs were grown to confluence before being treated with inhibitors or
agonists. Unless otherwise noted, cells in all experiments were preincu-
bated with vehicle (DMSO), with the ERK5 inhibitor XMD8-92 (5 mM, Axon
Medchem) or XMD17-109 (1 mM,Medchem Express), or with the MEK5
inhibitor BIX02189 (10 mM, Axon Medchem) for 1 hour before treatment
and then continuously during treatment with vehicle (0.9% saline) or the
inflammatory agonists Pam3Cys (10 mg/ml, EMC Microcollections), FSL-1
(10 mg/ml, EMC Microcollections), LPS (10 mg/ml, List Laboratories), re-
combinant human TNF-a (100 ng/ml, PeproTech Inc.), or IL-1b (0.1, 1, or
10 ng/ml, R&D Systems) for the times indicated in the figure legends. Prepa-
rations of XMD8-92, XMD17-109, BIX02189, Pam3Cys, FSL-1, and
TNF-a contained LPS (<0.1 endotoxin unit/ml) based on the limulus
amebocyte lysate endotoxin assay (Thermo Scientific).
Transfection of HMVEC-lung cells with siRNAs
MAPK7-specific (ERK5, L-003513-00-0005), MAP2K5-specific (MEK5,
L-003966-00-0005), and control (L-005120-01-0005) siRNAON-TARGETplus
SMARTpools (Thermo Scientific) were used according to the manufacturer’s
suggested protocol for the transfection of HUVECs with the DharmaFECT 4Fig. 8. ERK5 promotes cytokine secretion in a mouse model of lung IR injury. (A and B) Wild-type mice
were injected intraperitoneally with XMD8-92 (50 mg/kg) or vehicle [30% (2-hydroxypropyl)-b-cyclodextrin]
just before being subjected to ventilated lung IR injury as described in Materials and Methods. The con-
centrations of IL-6 and CCL2 in the plasma of the indicted mice were quantified 1 hour after reperfusion
(ischemia time, 30 min). Each point represents plasma from a single mouse. Data are from 6 to 10 mice per
group from a single experiment and are representative of two independent experiments. *P < 0.05 and
**P < 0.01 when comparing vehicle-treated mice with inhibitor-treated mice.August 2015 Vol 8 Issue 391 ra86 10
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 Transfection Reagent. In some cases, whole-cell lysates were prepared
72 hours after transfection, whereas cell culture media were collected
79 hours after transfection (which included 7 hours of treatment with
inhibitor and agonist).
Western blotting analysis
Cells were lysed with radioimmunoprecipitation assay lysis buffer [4 mM
sodium dihydrogen phosphate (pH 7.0), 6 mM disodium hydrogen phos-
phate (pH 7.0), 150 mM sodium chloride, 1%NP-40, 1% sodium deoxycho-
late, 0.1% SDS, 2 mM EDTA, 50 mM sodium fluoride, 0.1 mM sodium
orthovanadate] containing protease inhibitor cocktail (Sigma-Aldrich).
Total proteins were resolved by SDS–polyacrylamide gel electrophoresis
and then transferred onto polyvinylidene difluoride (PVDF) membranes
(Pall Corp). The membranes were blocked in 3% bovine serum albumin
(BSA) for 45 min at room temperature and then incubated with primary
antibody solution overnight at 4°C. The PVDF membranes were washed
and then incubated with the appropriate horseradish peroxidase–conjugated
secondary antibodies (Jackson ImmunoResearch). Western blots were de-
veloped with SuperSignal West Dura Extended Duration Substrate (Thermo
Scientific), and signals were detected with a Gel Logic 2200 Imaging Sys-
tem (Kodak) run on Carestream imaging software (Carestream Health).
Antibodies specific for ERK5 (Cell Signaling), ERK1/2 (Cell Signaling),
MEK5 (Millipore), MEK1/2 (R&D Systems), MEK4 (Antibodies On-
line), and b-actin (Sigma-Aldrich) were used for Western blotting analysis.
ELISAs and MTT assays
The concentrations of cytokines secreted by cells were quantified by anal-
ysis of cell culture media with ELISA kits specific for IL-6 (R&D Systems),
IL-8 (BD Biosciences), TNF-a (R&D Systems), CCL2/MCP-1 (R&D
Systems), and CCL3/MIP-1a (R&D Systems) according to the manufac-
turers’ instructions. Active PAI-1 was detected with the PAI-1 functional
assay ELISA kit (Molecular Innovations). MTT assays (Biotium) were per-
formed in 96-well plates according to the manufacturer’s instructions.
Neutrophil adhesion assay
The neutrophil adhesion assay was performed as described previously
(104). Briefly, neutrophils were resuspended in RPMI 1640 medium (2 ×
106 cells/ml) and labeled with 3 mM calcein AM (Life Technologies). Im-
mediately before the labeled neutrophils were added, 48-well plates
containingmonolayers of HMVEC-lung cells werewashed three times with
RPMI 1640 medium containing 3% BSA. The labeled neutrophils were then
added at 3 × 105 to 6 × 105 cells per well and allowed to incubate for 20min
at 37°C in the dark before being washed five times with PBS to remove
nonadherent cells. Pre- and post-wash fluorescence were read at an exci-
tation of 485 nm and an emission of 520 nm in a FLUOstar OPTIMA
fluorescent plate reader. The relative adherence was then calculated. Neu-
trophil adhesion was visualized with a Zeiss Axio Imager D1 microscope.
Challenge of mice with saline, Pam3Cys,
LPS, or HKSA
All animal study protocols were approved by the University of California
San Francisco (UCSF) Animal Care and Use Committee. Eight-week-old
C57BL/6J male mice (The Jackson Laboratory) were injected intraperi-
toneally with XMD8-92 (50 mg/kg) or XMD17-109 (50 mg/kg) dissolved
in 30% (2-hydroxypropyl)-b-cyclodextrin or with BIX02189 (25 mg/kg)
dissolved in 5% DMSO containing 30% (2-hydroxypropyl)-b-cyclodextrin,
or with vehicle alone [30% (2-hydroxypropyl)-b-cyclodextrin with or with-
out 5% DMSO] 30 min before being injected intravenously (“challenged”)
with either 0.9% saline, Pam3Cys (2.5 mg/kg), LPS (10 mg/kg), or HKSA
(Invivogen) at 2.5 × 1010 bacteria/kg. In each experiment, four mice werewwwused per condition. The doses of Pam3Cys, LPS, and HKSA that were used
were established in pilot dose-response studies. Comparisons were made
between mice that were treated with the ERK5 or MEK5 inhibitors and
control mice that were treated with vehicle alone.
Analysis of LPS-induced mortality in mice
Eight-week-old C57BL/6J male mice were injected intraperitoneally with
XMD8-92 (50 mg/kg) dissolved in 30% (2-hydroxypropyl)-b-cyclodextrin
or vehicle [30% (2-hydroxypropyl)-b-cyclodextrin] alone 30 min before or
1 hour after the mice were injected intraperitoneally with LPS at 15 and
12.5 mg/kg, respectively. For inhibitor pretreatment experiments, eight
mice per group were used, whereas for inhibitor posttreatment experi-
ments, 14 mice per group were used. Mice were monitored by an individ-
ual who was blinded to the treatment group at 4 hours, 8 hours, and then
every 8 hours up to 72 hours after the mice were challenged with LPS.
Mice that became moribund were euthanized and were counted among the
mice that died without the need for euthanasia. A moribund state, which is
defined as inanition, the lack of response to gentle shaking of the cage, and
the inability of the mice to right themselves when placed on their sides are
uniform presages for death in endotoxemic mice.
Ventilated lung IR injury induced by left pulmonary
artery occlusion
A mouse model of unilateral left pulmonary artery occlusion was used, as
described previously (108). Fifteen-week-old C57BL/6J male mice were
anesthetized by intraperitoneal administration of tribromoethanol (also
known as Avertin), endotracheally intubated, and placed on a ventilator
(with tidal volumes of 225 ml and a respiratory rate of 180 breaths/min
for a 30-g mouse) and were given buprenorphine intraperitoneally. The mice
underwent a left thoracotomy through the interspace between the second
and third ribs, after which the left pulmonary artery was identified, and an
8-0 Prolene monofilament suture was passed between the left pulmonary
artery and the left bronchus while visualizing under a high-magnification
microscope. A slip-knot suture was tied such that the end of the suture was
externalized through a narrow bore (27-gauge) needle to the anterior
chest wall. Before closure of the thorax, the left lung was inflated to oc-
cupy the left thoracic cavity. Local anesthetic (three to four drops of 0.25%
bupivacaine) was applied topically before skin closure. The total period of
mechanical ventilation was about 20 to 25 min. After the skin was closed,
the mice were allowed to recover from anesthesia, mechanical ventilation
was discontinued, and the endotracheal tube was removed. After 30 min of
ischemia, reperfusion was established by removing the externalized suture.
At the end of a 1-hour reperfusion period, blood was collected into a he-
parinized syringe by cardiac puncture under deep anesthesia and was then
centrifuged at 14,000g for 5 min before the plasma was stored at −80°C.
For the sham procedure, mice underwent left thoracotomy and all of the
other procedures that were described earlier; however, the left pulmonary
artery was not isolated and a slip knot was not tied or externalized. Blood
from these animals was collected at the same time intervals as were used for
the experimental group. Mice that died before the completion of surgery,
yielded insufficient blood volumes, or had inadvertent esophageal intuba-
tion were excluded from the analysis.
Statistical analysis
Data from in vitro and in vivo experiments were analyzed in GraphPad Prism
with Mann-Whitney or Kruskal-Wallis nonparametric-based biostatistics,
except for the data from the endotoxemic mortality experiments, which
were analyzed with Kaplan-Meier curves. P ≤ 0.05 was considered to
be statistically significant for all data, and the data in graphs are presented
as means ± SD..SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 11
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 SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/8/391/ra86/DC1
Fig. S1. Domain organization of ERK5.
Fig. S2. XMD8-92, XMD17-109, and BIX02189 have no substantial effects on cell viability.
Fig. S3. The ERK5 inhibitor XMD8-92 reduces the amounts of proinflammatory cytokines
secreted by HMVEC-lung cells when it is added before or after they are treated with LPS.
Fig. S4. MEK5 promotes the binding of neutrophils to activated ECs.
Fig. S5. ERK5 promotes the secretion of CCL2 and enhances PAI-1 activity in mice 24 hours
after they are challenged with LPS.
REFERENCES AND NOTES
1. K. Ley, C. Laudanna, M. I. Cybulsky, S. Nourshargh, Getting to the site of inflammation:
The leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678–689 (2007).
2. R. Medzhitov, Origin and physiological roles of inflammation. Nature 454, 428–435
(2008).
3. A. Zarbock, K. Ley, Mechanisms and consequences of neutrophil interaction with
the endothelium. Am. J. Pathol. 172, 1–7 (2008).
4. A. Iwasaki, R. Medzhitov, Regulation of adaptive immunity by the innate immune
system. Science 327, 291–295 (2010).
5. S. Hirsiger, H.-P. Simmen, C. M. L. Werner, G. A. Wanner, D. Rittirsch, Danger
signals activating the immune response after trauma. Mediators Inflamm. 2012, 1–10
(2012).
6. U. Jaffer, R. G. Wade, T. Gourlay, Cytokines in the systemic inflammatory response
syndrome: A review. HSR Proc. Intensive Care Cardiovasc. Anesth. 2, 161–175 (2010).
7. A. Lenz, G. A. Franklin, W. G. Cheadle, Systemic inflammation after trauma. Injury
38, 1336–1345 (2007).
8. D. Rittirsch, M. A. Flierl, P. A. Ward, Harmful molecular mechanisms in sepsis. Nat. Rev.
Immunol. 8, 776–787 (2008).
9. M. Schouten, W. J. Wiersinga, M. Levi, T. van der Poll, Inflammation, endothelium,
and coagulation in sepsis. J. Leukoc. Biol. 83, 536–545 (2008).
10. M. Levi, E. de Jonge, T. van der Poll, Sepsis and disseminated intravascular coagulation.
J. Thromb. Thrombolysis 16, 43–47 (2003).
11. N. Semeraro, C. T. Ammollo, F. Semeraro, M. Colucci, Sepsis, thrombosis and organ
dysfunction. Thromb. Res. 129, 290–295 (2012).
12. H. C. Kwaan, Microvascular thrombosis: A serious and deadly pathologic process in
multiple diseases. Semin. Thromb. Hemost. 37, 961–978 (2011).
13. R. M. Durham, J. J. Moran, J. E. Mazuski, M. J. Shapiro, A. E. Baue, L. M. Flint,
Multiple organ failure in trauma patients. J. Trauma 55, 608–616 (2003).
14. G. S. Martin, D. M. Mannino, S. Eaton, M. Moss, The epidemiology of sepsis in the
United States from 1979 through 2000. N. Engl. J. Med. 348, 1546–1554 (2003).
15. V. D. Mayr, M.W. Dünser, V. Greil, S. Jochberger, G. Luckner, H. Ulmer, B. E. Friesenecker,
J. Takala, W. R. Hasibeder, Causes of death and determinants of outcome in critically ill
patients. Crit. Care 10, R154 (2006).
16. Y. Sakr, S. M. Lobo, R. P. Moreno, H. Gerlach, V. M. Ranieri, A. Michalopoulos,
J.-L. Vincent; SOAP Investigators, Patterns and early evolution of organ failure in the
intensive care unit and their relation to outcome. Crit. Care 16, R222 (2012).
17. M. J. Hickey, P. Kubes, Intravascular immunity: The host–pathogen encounter in
blood vessels. Nat. Rev. Immunol. 9, 364–375 (2009).
18. B. McDonald, K. Pittman, G. B. Menezes, S. A. Hirota, I. Slaba, C. C. M. Waterhouse,
P. L. Beck, D. A. Muruve, P. Kubes, Intravascular danger signals guide neutrophils to
sites of sterile inflammation. Science 330, 362–366 (2010).
19. G. Y. Chen, G. Nuñez, Sterile inflammation: Sensing and reacting to damage. Nat. Rev.
Immunol. 10, 826–837 (2010).
20. D. Rittirsch, H. Redl, M. Huber-Lang, Role of complement in multiorgan failure. Clin.
Dev. Immunol. 2012, 962927 (2012).
21. T. Kawai, S. Akira, The role of pattern-recognition receptors in innate immunity: Update
on Toll-like receptors. Nat. Immunol. 11, 373–384 (2010).
22. H.-S. Shin, F. Xu, A. Bagchi, E. Herrup, A. Prakash, C. Valentine, H. Kulkarni, K. Wilhelmsen,
S. Warren, J. Hellman, Bacterial lipoprotein TLR2 agonists broadly modulate endothelial
function and coagulation pathways in vitro and in vivo. J. Immunol. 186, 1119–1130
(2011).
23. K. Wilhelmsen, K. R. Mesa, J. Lucero, F. Xu, J. Hellman, ERK5 protein promotes,
whereas MEK1 protein differentially regulates, the Toll-like receptor 2 protein-
dependent activation of human endothelial cells and monocytes. J. Biol. Chem.
287, 26478–26494 (2012).
24. T. Collins, M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, T. Maniatis, Transcrip-
tional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible
enhancers. FASEB J. 9, 899–909 (1995).
25. K. Wilhelmsen, K. R. Mesa, A. Prakash, F. Xu, J. Hellman, Activation of endothelial
TLR2 by bacterial lipoprotein upregulates proteins specific for the neutrophil response.
Innate Immun. 18, 602–616 (2012).
26. T. Iwaki, T. Urano, K. Umemura, PAI-1, progress in understanding the clinical problem
and its aetiology. Br. J. Haematol. 157, 291–298 (2012).www27. S. Gando, Role of fibrinolysis in sepsis. Semin. Thromb. Hemost. 39, 392–399
(2013).
28. R. M. Mesters, N. Florke, H. Ostermann, J. Kienast, Increase of plasminogen acti-
vator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
Thromb. Haemost. 75, 902–907 (1996).
29. C. D. Buckley, D. W. Gilroy, C. N. Serhan, Proresolving lipid mediators and mechanisms
in the resolution of acute inflammation. Immunity 40, 315–327 (2014).
30. J. S. C. Arthur, S. C. Ley, Mitogen-activated protein kinases in innate immunity. Nat.
Rev. Immunol. 13, 679–692 (2013).
31. M. Cargnello, P. P. Roux, Activation and function of the MAPKs and their substrates,
the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50–83 (2011).
32. S. Vallabhapurapu, M. Karin, Regulation and function of NF-kB transcription factors
in the immune system. Annu. Rev. Immunol. 27, 693–733 (2009).
33. C. Widmann, S. Gibson, M. B. Jarpe, G. L. Johnson, Mitogen-activated protein ki-
nase: Conservation of a three-kinase module from yeast to human. Physiol. Rev. 79,
143–180 (1999).
34. P. Cohen, Targeting protein kinases for the development of anti-inflammatory drugs.
Curr. Opin. Cell Biol. 21, 317–324 (2009).
35. G. Zhou, Z. Q. Bao, J. E. Dixon, Components of a new human protein kinase signal
transduction pathway. J. Biol. Chem. 270, 12665–12669 (1995).
36. J. M. English, C. A. Vanderbilt, S. Xu, S. Marcus, M. H. Cobb, Isolation of MEK5 and
differential expression of alternatively spliced forms. J. Biol. Chem. 270, 28897–28902
(1995).
37. J. D. Lee, R. J. Ulevitch, J. H. Han, Primary structure of BMK1: A new mammalian
map kinase. Biochem. Biophys. Res. Commun. 213, 715–724 (1995).
38. G. N. Nithianandarajah-Jones, B. Wilm, C. E. P. Goldring, J. Müller, M. J. Cross,
ERK5: Structure, regulation and function. Cell. Signal. 24, 2187–2196 (2012).
39. N. Mody, D. G. Campbell, N. Morrice, M. Peggie, P. Cohen, An analysis of the phos-
phorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5)
by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem. J. 372, 567–575
(2003).
40. H. Morimoto, K. Kondoh, S. Nishimoto, K. Terasawa, E. Nishida, Activation of a C-
terminal transcriptional activation domain of ERK5 by autophosphorylation. J. Biol.
Chem. 282, 35449–35456 (2007).
41. M. Hayashi, R. I. Tapping, T.-H. Chao, J.-F. Lo, C. C. King, Y. Yang, J.-D. Lee,
BMK1 mediates growth factor-induced cell proliferation through direct cellular acti-
vation of serum and glucocorticoid-inducible kinase. J. Biol. Chem. 276, 8631–8634
(2001).
42. S. J. Cameron, S. Malik, M. Akaike, N. Lerner-Marmarosh, C. Yan, J.-D. Lee, J.-i. Abe,
J. Yang, Regulation of epidermal growth factor-induced connexin 43 gap junction
communication by big mitogen-activated protein kinase 1/ERK5 but not ERK1/2 kinase
activation. J. Biol. Chem. 278, 18682–18688 (2003).
43. M. Kim, S. Kim, J. H. Lim, C. Lee, H. C. Choi, C. H. Woo, Laminar flow activation of
ERK5 protein in vascular endothelium leads to atheroprotective effect via NF-E2-related
factor 2 (Nrf2) activation. J. Biol. Chem. 287, 40722–40731 (2012).
44. P. R. Clark, T. J. Jensen, M. S. Kluger, M. Morelock, A. Hanidu, Z. Qi, R. J. Tatake,
J. S. Pober, MEK5 is activated by shear stress, activates ERK5 and induces
KLF4 to modulate TNF responses in human dermal microvascular endothelial cells.
Microcirculation 18, 102–117 (2011).
45. N. Ohnesorge, D. Viemann, N. Schmidt, T. Czymai, D. Spiering, M. Schmolke, S. Ludwig,
J. Roth, M. Goebeler, M. Schmidt, Erk5 activation elicits a vasoprotective endothelial
phenotype via induction of Krüppel-like factor 4 (KLF4). J. Biol. Chem. 285, 26199–26210
(2010).
46. T. Sasaki, H. Kojima, R. Kishimoto, A. Ikeda, H. Kunimoto, K. Nakajima, Spatiotemporal
regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role.
Mol. Cell 24, 63–75 (2006).
47. C.-H.Woo, M. P. Massett, T. Shishido, S. Itoh, B. Ding, C. McClain, W. Che, S. R. Vulapalli,
C. Yan, J.-i. Abe, ERK5 activation inhibits inflammatory responses via peroxisome
proliferator-activated receptor d (PPARd) stimulation. J. Biol. Chem. 281, 32164–32174
(2006).
48. M. Akaike, W. Che, N.-L. Marmarosh, S. Ohta, M. Osawa, B. Ding, B. C. Berk, C. Yan,
J.-i. Abe, The hinge-helix 1 region of peroxisome proliferator-activated receptor
g1 (PPARg1) mediates interaction with extracellular signal-regulated kinase 5 and
PPARg1 transcriptional activation: Involvement in flow-induced PPARg activation in
endothelial cells. Mol. Cell. Biol. 24, 8691–8704 (2004).
49. K. Terasawa, K. Okazaki, E. Nishida, Regulation of c-Fos and Fra-1 by the MEK5-ERK5
pathway. Genes Cells 8, 263–273 (2003).
50. Y. Kato, M. Zhao, A. Morikawa, T. Sugiyama, D. Chakravortty, N. Koide, T. Yoshida,
R. I. Tapping, Y. Yang, T. Yokochi, J.-D. Lee, Big mitogen-activated kinase regulates
multiple members of the MEF2 protein family. J. Biol. Chem. 275, 18534–18540
(2000).
51. C. C. Yang, O. I. Ornatsky, J. C. McDermott, T. F. Cruz, C. A. Prody, Interaction of
myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/
BMK1. Nucleic Acids Res. 26, 4771–4777 (1998)..SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 12
R E S E A R C H A R T I C L E
 o
n
 N
ovem
ber 26, 2016
http://stke.sciencem
ag.org/
D
ow
nloaded from
 52. J. M. English, G. Pearson, R. Baer, M. H. Cobb, Identification of substrates and reg-
ulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases.
J. Biol. Chem. 273, 3854–3860 (1998).
53. Y. Kato, V. V. Kravchenko, R. I. Tapping, J. Han, R. J. Ulevitch, J.-D. Lee, BMK1/
ERK5 regulates serum-induced early gene expression through transcription factor
MEF2C. EMBO J. 16, 7054–7066 (1997).
54. M. Buschbeck, A. Ullrich, The unique C-terminal tail of the mitogen-activated protein
kinase ERK5 regulates its activation and nuclear shuttling. J. Biol. Chem. 280,
2659–2667 (2005).
55. F. A. Iñesta-Vaquera, D. G. Campbell, J. S. C. Arthur, A. Cuenda, ERK5 pathway
regulates the phosphorylation of tumour suppressor hDlg during mitosis. Biochem.
Biophys. Res. Commun. 399, 84–90 (2010).
56. A. Ranganathan, G. W. Pearson, C. A. Chrestensen, T. W. Sturgill, M. H. Cobb, The
MAP kinase ERK5 binds to and phosphorylates p90 RSK. Arch. Biochem. Biophys.
449, 8–16 (2006).
57. B.-e. Xu, S. Stippec, L. Lenertz, B.-H. Lee, W. Zhang, Y.-K. Lee, M. H. Cobb, WNK1
activates ERK5 by an MEKK2/3-dependent mechanism. J. Biol. Chem. 279, 7826–7831
(2004).
58. Q. Zheng, G. Yin, C. Yan, M. Cavet, B. C. Berk, 14-3-3b binds to big mitogen-activated
protein kinase 1 (BMK1/ERK5) and regulates BMK1 function. J. Biol. Chem. 279,
8787–8791 (2004).
59. W. Sun, X.Wei, K. Kesavan, T. P. Garrington, R. Fan, J. Mei, S. M. Anderson, E.W.Gelfand,
G. L. Johnson, MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-
regulated kinase 5 activation by epidermal growth factor via Src. Mol. Cell. Biol. 23,
2298–2308 (2003).
60. W. Sun, K. Kesavan, B. C. Schaefer, T. P. Garrington, M.Ware, N. L. Johnson, E.W.Gelfand,
G. L. Johnson, MEKK2 associates with the adapter protein Lad/RIBP and regulates the
MEK5-BMK1/ERK5 pathway. J. Biol. Chem. 276, 5093–5100 (2001).
61. S. J. Sohn, B. K. Sarvis, D. Cado, A. Winoto, ERK5 MAPK regulates embryonic
angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial
growth factor expression. J. Biol. Chem. 277, 43344–43351 (2002).
62. L. Yan, J. Carr, P. R. Ashby, V. Murry-Tait, C. Thompson, J. S. C. Arthur, Knockout
of ERK5 causes multiple defects in placental and embryonic development. BMC
Dev. Biol. 3, 11 (2003).
63. C. P. Regan, W. Li, D. M. Boucher, S. Spatz, M. S. Su, K. Kuida, Erk5 null mice
display multiple extraembryonic vascular and embryonic cardiovascular defects.
Proc. Natl. Acad. Sci. U.S.A. 99, 9248–9253 (2002).
64. M. Hayashi, S.-W. Kim, K. Imanaka-Yoshida, T. Yoshida, E. D. Abel, B. Eliceiri, Y. Yang,
R. J. Ulevitch, J.-D. Lee, Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular
integrity and leads to endothelial failure. J. Clin. Invest. 113, 1138–1148 (2004).
65. O. L. Roberts, K. Holmes, J. Müller, D. A. E. Cross, M. J. Cross, ERK5 and the
regulation of endothelial cell function. Biochem. Soc. Trans. 37, 1254–1259 (2009).
66. Y. W. Pan, J. Zou, W.Wang, H. Sakagami, M. G. Garelick, G. Abel, C. T. Kuo, D. R. Storm,
Z. Xia, Inducible and conditional deletion of extracellular signal-regulated kinase 5
disrupts adult hippocampal neurogenesis. J. Biol. Chem. 287, 23306–23317
(2012).
67. Y. W. Pan, C. T. Kuo, D. R. Storm, Z. Xia, Inducible and targeted deletion of the
ERK5 MAP kinase in adult neurogenic regions impairs adult neurogenesis in the
olfactory bulb and several forms of olfactory behavior. PLOS One 8, e49622 (2013).
68. O. Ananieva, A. Macdonald, X. Wang, C. E. McCoy, J. McIlrath, C. Tournier, J. S. C. Arthur,
ERK5 regulation in naïve T-cell activation and survival. Eur. J. Immunol. 38, 2534–2547
(2008).
69. T. Li, Y.-W. Pan, W. Wang, G. Abel, J. Zou, L. Xu, D. R. Storm, Z. Xia, Targeted
deletion of the ERK5 MAP kinase impairs neuronal differentiation, migration, and
survival during adult neurogenesis in the olfactory bulb. PLOS One 8, e61948 (2013).
70. J. Zou, Y.-W. Pan, Z. Wang, S.-Y. Chang, W. Wang, X. Wang, C. Tournier, D. R. Storm,
Z. Xia, Targeted deletion of ERK5 MAP kinase in the developing nervous system im-
pairs development of GABAergic interneurons in the main olfactory bulb and behavioral
discrimination between structurally similar odorants. J. Neurosci. 32, 4118–4132 (2012).
71. W. Wang, Y.-W. Pan, T. Wietecha, J. Zou, G. M. Abel, C. T. Kuo, Z. Xia, Extracellular
signal-regulated kinase 5 (ERK5) mediates prolactin-stimulated adult neurogenesis in
the subventricular zone and olfactory bulb. J. Biol. Chem. 288, 2623–2631 (2013).
72. R. J. Tatake, M. M. O’Neill, C. A. Kennedy, A. L. Wayne, S. Jakes, D. Wu, S. Z. Kugler
Jr., M. A. Kashem, P. Kaplita, R. J. Snow, Identification of pharmacological inhibitors of
the MEK5/ERK5 pathway. Biochem. Biophys. Res. Commun. 377, 120–125 (2008).
73. P. T. Flaherty, I. Chopra, P. Jain, D. Monlish, J. Cavanaugh, Structure–activity relation-
ships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5
signaling pathway. Bioorg. Med. Chem. 18, 8054–8060 (2010).
74. P. T. Flaherty, I. Chopra, P. Jain, S. Yi, E. Allen, J. Cavanaugh, Identification of
benzimidazole-based inhibitors of the mitogen activated kinase-5 signaling pathway.
Bioorg. Med. Chem. Lett. 20, 2892–2896 (2010).
75. Q. Yang, X. Deng, B. Lu, M. Cameron, C. Fearns, M. P. Patricelli, J. R. Yates III, N. S. Gray,
J. D. Lee, Pharmacological inhibition of BMK1 suppresses tumor growth through pro-
myelocytic leukemia protein. Cancer Cell 18, 258–267 (2010).www76. S. Álvarez-Fernández, M. J. Ortiz-Ruiz, T. Parrott, S. Zaknoen, E. M. Ocio, J. San Miguel,
F. J. Burrows, A. Esparís-Ogando, A. Pandiella, Potent antimyeloma activity of a novel
ERK5/CDK inhibitor. Clin. Cancer Res. 19, 2677–2687 (2013).
77. Q. Yang, J.-D. Lee, Targeting the BMK1 MAP kinase pathway in cancer therapy.
Clin. Cancer Res. 17, 3527–3532 (2011).
78. J. C. Montero, A. Ocaña, M. Abad, M. J. Ortiz-Ruiz, A. Pandiella, A. Esparís-Ogando,
Expression of Erk5 in early stage breast cancer and association with disease free sur-
vival identifies this kinase as a potential therapeutic target. PLOS One 4, e5565 (2009).
79. P. B. Mehta, B. L. Jenkins, L. McCarthy, L. Thilak, C. N. Robson, D. E. Neal, H. Y. Leung,
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates
proliferation, MMP-9 expression and invasion. Oncogene 22, 1381–1389 (2003).
80. C. Sticht, K. Freier, K. Knöpfle, C. Flechtenmacher, S. Pungs, C. Hofele, M. Hahn, S. Joos,
P. Lichter, Activation of MAP kinase signaling through ERK5 but not ERK1 expression
is associated with lymph node metastases in oral squamous cell carcinoma (OSCC).
Neoplasia 10, 462–470 (2008).
81. C. B.Weldon, A. B. Scandurro, K. W. Rolfe, J. L. Clayton, S. Elliott, N. N. Butler, L. I. Melnik,
J. Alam, J. A. McLachlan, B. M. Jaffe, B. S. Beckman, M. E. Burow, Identification of
mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells
by using gene expression microarray. Surgery 132, 293–301 (2002).
82. A. Esparís-Ogando, E. Díaz-Rodríguez, J. C. Montero, L. Yuste, P. Crespo, A. Pandiella,
Erk5 participates in neuregulin signal transduction and is constitutively active in breast
cancer cells overexpressing ErbB2. Mol. Cell. Biol. 22, 270–285 (2002).
83. S. Nagel, C. Burek, L. Venturini, M. Scherr, H. Quentmeier, C. Meyer, A. Rosenwald,
H. G. Drexler, R. A. F. MacLeod, Comprehensive analysis of homeobox genes in
Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated
via ERK5 signaling and BMI1. Blood 109, 3015–3023 (2007).
84. M. E. Ramos-Nino, S. R. Blumen, T. Sabo-Attwood, H. Pass, M. Carbone, J. R. Testa,
D. A. Altomare, B. T. Mossman, HGF mediates cell proliferation of human mesothelioma
cells through a PI3K/MEK5/Fra-1 pathway. Am. J. Respir. Cell Mol. Biol. 38, 209–217
(2008).
85. J. Garaude, S. Cherni, S. Kaminski, E. Delepine, C. Chable-Bessia, M. Benkirane, J. Borges,
A. Pandiella, M. A. Iñiguez, M. Fresno, R. A. Hipskind, M. Villalba, ERK5 activates NF-kB in
leukemic T cells and is essential for their growth in vivo. J. Immunol. 177, 7607–7617
(2006).
86. M. Hayashi, C. Fearns, B. Eliceiri, Y. Yang, J.-D. Lee, Big mitogen-activated protein
kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for
tumor-associated angiogenesis. Cancer Res. 65, 7699–7706 (2005).
87. S. R. C. McCracken, A. Ramsay, R. Heer, M. E. Mathers, B. L. Jenkins, J. Edwards,
C. N. Robson, R. Marquez, P. Cohen, H. Y. Leung, Aberrant expression of extracellular
signal-regulated kinase 5 in human prostate cancer. Oncogene 27, 2978–2988 (2008).
88. A. K. Ramsay, S. R. C. McCracken, M. Soofi, J. Fleming, A. X. Yu, I. Ahmad, R. Morland,
L. Machesky, C. Nixon, D. R. Edwards, R. K. Nuttall, M. Seywright, R. Marquez, E. Keller,
H. Y. Leung, ERK5 signalling in prostate cancer promotes an invasive phenotype. Br. J.
Cancer 104, 664–672 (2011).
89. K. Wu, S. Tian, H. Zhou, Y. Wu, Statins protect human endothelial cells from TNF-
induced inflammation via ERK5 activation. Biochem. Pharmacol. 85, 1753–1760 (2013).
90. K.-S. Heo, E. Chang, N.-T. Le, H. Cushman, E. T. H. Yeh, K. Fujiwara, J.-i. Abe, De-
SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed
flow–induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction
and atherosclerosis. Circ. Res. 112, 911–923 (2013).
91. L. Li, R. J. Tatake, K. Natarajan, Y. Taba, G. Garin, C. Tai, E. Leung, J. Surapisitchat,
M. Yoshizumi, C. Yan, J.-i. Abe, B. C. Berk, Fluid shear stress inhibits TNF-mediated
JNK activation via MEK5–BMK1 in endothelial cells. Biochem. Biophys. Res. Commun.
370, 159–163 (2008).
92. N. T. Le, Y. Takei, Y. Izawa-Ishizawa, K. S. Heo, H. Lee, A. V. Smrcka, B. L. Miller,
K. A. Ko, S. Ture, C. Morrell, K. Fujiwara, M. Akaike, J. I. Abe, Identification of activators
of ERK5 transcriptional activity by high-throughput screening and the role of endothelial
ERK5 in vasoprotective effects induced by statins and antimalarial agents. J. Immunol.
193, 3803–3815 (2014).
93. D. Z. Mackesy, M. L. Goalstone, Extracellular signal-regulated kinase-5: Novel mediator
of insulin and tumor necrosis factor a-stimulated vascular cell adhesion molecule-1 ex-
pression in vascular cells. J. Diabetes 6, 595–602 (2014).
94. G. C. Luerman, C. Nguyen, H. Samaroo, P. Loos, H. Xi, A. Hurtado-Lorenzo, E. Needle,
G. Stephen Noell, P. Galatsis, J. Dunlop, K. F. Geoghegan, W. D. Hirst, Phosphopro-
teomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals
significant off-target effects of LRRK-2-IN-1. J. Neurochem. 128, 561–576 (2014).
95. J.-L. Sun, C. Xiao, B. Lu, J. Zhang, X.-z. Yuan, W. Chen, L.-N. Yu, F.-J. Zhang, G. Chen,
M. Yan, CX3CL1/CX3CR1 regulates nerve injury-induced pain hypersensitivity through
the ERK5 signaling pathway. J. Neurosci. Res. 91, 545–553 (2013).
96. S. Kim, J. H. Lim, C. H. Woo, ERK5 inhibition ameliorates pulmonary fibrosis via
regulating Smad3 acetylation. Am. J. Pathol. 183, 1758–1768 (2013).
97. W. Zhu, J. S. Downey, J. Gu, F. Di Padova, H. Gram, J. Han, Regulation of TNF
expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 164,
6349–6358 (2000)..SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 13
R E S E A R C H A R T I C L E
 o
n
 N
ovem
ber 26, 2016
http://stke.sciencem
ag.org/
D
ow
nloaded from
 98. C. S. Hii, D. S. Anson, M. Costabile, V. Mukaro, K. Dunning, A. Ferrante, Charac-
terization of the MEK5-ERK5 module in human neutrophils and its relationship to
ERK1/ERK2 in the chemotactic response. J. Biol. Chem. 279, 49825–49834 (2004).
99. R. Ahmad, P. K. Shihab, S. Jasem, K. Behbehani, FSL-1 induces MMP-9 production
through TLR-2 and NF-kB/AP-1 signaling pathways in monocytic THP-1 cells. Cell.
Physiol. Biochem. 34, 929–942 (2014).
100. J. M. Elkins, J. Wang, X. Deng, M. J. Pattison, J. S. C. Arthur, T. Erazo, N. Gomez,
J. M. Lizcano, N. S. Gray, S. Knapp, X-ray crystal structure of ERK5 (MAPK7) in
complex with a specific inhibitor. J. Med. Chem. 56, 4413–4421 (2013).
101. X. Deng, J. M. Elkins, J. Zhang, Q. Yang, T. Erazo, N. Gomez, H. G. Choi, J. Wang,
N. Dzamko, J.-D. Lee, T. Sim, N. Kim, D. R. Alessi, J. M. Lizcano, S. Knapp, N. S. Gray,
Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of
benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur. J. Med. Chem. 70, 758–767 (2013).
102. G. Glatz, G. Gógl, A. Alexa, A. Reményi, Structural mechanism for the specific
assembly and activation of the extracellular signal regulated kinase 5 (ERK5)
module. J. Biol. Chem. 288, 8596–8609 (2013).
103. A. Lin, A. Minden, H. Martinetto, F. X. Claret, C. Lange-Carter, F. Mercurio, G. L. Johnson,
M. Karin, Identification of a dual specificity kinase that activates the Jun kinases and
p38-Mpk2. Science 268, 286–290 (1995).
104. K. Wilhelmsen, K. Farrar, J. Hellman, Quantitative in vitro assay to measure neutrophil
adhesion to activated primary human microvascular endothelial cells under static
conditions. J. Vis. Exp. e50677 (2013).
105. M. C. de Almeida, A. C. Silva, A. Barral, M. Barral Netto, A simple method for human
peripheral blood monocyte isolation. Mem. Inst. Oswaldo Cruz 95, 221–223 (2000).
106. S. Pfeiler, S. Massberg, B. Engelmann, Biological basis and pathological relevance
of microvascular thrombosis. Thromb. Res. 133 (Suppl.1), S35–S37 (2014).
107. D. De Backer, D. Orbegozo Cortes, K. Donadello, J.-L. Vincent, Pathophysiology of micro-
circulatory dysfunction and the pathogenesis of septic shock. Virulence 5, 73–79 (2014).
108. A. Prakash, K. R. Mesa, K. Wilhelmsen, F. Xu, J. M. Dodd-o, J. Hellman, Alveolar
macrophages and Toll-like receptor 4 mediate ventilated lung ischemia reperfusion
injury in mice. Anesthesiology 117, 822–835 (2012).
109. T.-H. Chao, M. Hayashi, R. I. Tapping, Y. Kato, J.-D. Lee, MEKK3 directly regulates
MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling
pathway. J. Biol. Chem. 274, 36035–36038 (1999).
110. M. Chiariello, M. J. Marinissen, J. S. Gutkind, Multiple mitogen-activated protein ki-
nase signaling pathways connect the cot oncoprotein to the c-jun promoter and to
cellular transformation. Mol. Cell. Biol. 20, 1747–1758 (2000).
111. M. P. Belich, A. Salmerón, L. H. Johnston, S. C. Ley, TPL-2 kinase regulates the pro-
teolysis of the NF-kB-inhibitory protein NF-kB1 p105. Nature 397, 363–368 (1999).
112. J. M. English, G. Pearson, T. Hockenberry, L. Shivakumar, M. A. White, M. H. Cobb,
Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J.
Biol. Chem. 274, 31588–31592 (1999).
113. S. Kamakura, T. Moriguchi, E. Nishida, Activation of the protein kinase ERK5/BMK1
by receptor tyrosine kinases. Identification and characterization of a signaling
pathway to the nucleus. J. Biol. Chem. 274, 26563–26571 (1999).
114. H. J. Yoon, S.-B. Jeon, I.-H. Kim, E. J. Park, Regulation of TLR2 expression by
prostaglandins in brain glia. J. Immunol. 180, 8400–8409 (2008).
115. T.-H. Han, R. Prywes, Regulatory role of MEF2D in serum induction of the c-jun
promoter. Mol. Cell. Biol. 15, 2907–2915 (1995).
116. E. Shaulian, M. Karin, AP-1 in cell proliferation and survival. Oncogene 20, 2390–2400
(2001).
117. R. Zenz, R. Eferl, C. Scheinecker, K. Redlich, J. Smolen, H. B. Schonthaler, L. Kenner,
E. Tschachler, E. F. Wagner, Activator protein 1 (Fos/Jun) functions in inflammatory
bone and skin disease. Arthritis Res. Ther. 10, 201 (2008).www118. M. Karin, Inflammation-activated protein kinases as targets for drug development.
Proc. Am. Thorac. Soc. 2, 386–390; discussion 394–395 (2005).
119. S. J. Sohn, D. Li, L. K. Lee, A. Winoto, Transcriptional regulation of tissue-specific
genes by the ERK5 mitogen-activated protein kinase. Mol. Cell. Biol. 25, 8553–8566
(2005).
120. J. Zahlten, R. Steinicke, B. Opitz, J. Eitel, P. D. N’Guessan, M. Vinzing, M. Witzenrath,
B. Schmeck, S. Hammerschmidt, N. Suttorp, S. Hippenstiel, TLR2- and nucleotide-
binding oligomerization domain 2-dependent Krüppel-like factor 2 expression down-
regulates NF-kB–related gene expression. J. Immunol. 185, 597–604 (2010).
121. S. SenBanerjee, Z. Lin, G. B. Atkins, D. M. Greif, R. M. Rao, A. Kumar, M. W. Feinberg,
Z. Chen, D. I. Simon, F.W. Luscinskas, T. M.Michel, M. A. Gimbrone Jr., G. García-Cardeña,
M. K. Jain, KLF2 is a novel transcriptional regulator of endothelial proinflammatory
activation. J. Exp. Med. 199, 1305–1315 (2004).
122. Z. Lin, A. Kumar, S. SenBanerjee, K. Staniszewski, K. Parmar, D. E. Vaughan,
M. A. Gimbrone Jr., V. Balasubramanian, G. García-Cardeña, M. K. Jain, Kruppel-like
factor 2 (KLF2) regulates endothelial thrombotic function. Circ. Res. 96, 48–57 (2005).
123. R. Bhattacharya, S. Senbanerjee, Z. Lin, S. Mir, A. Hamik, P. Wang, P. Mukherjee,
D. Mukhopadhyay, M. K. Jain, Inhibition of vascular permeability factor/vascular en-
dothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J. Biol.
Chem. 280, 28848–28851 (2005).
124. R. A. Boon, A. J. G. Horrevoets, Key transcriptional regulators of the vasoprotective
effects of shear stress. Hamostaseologie 29, 39–43 (2009).
125. A. R. Kinderlerer, F. Ali, M. Johns, E. A. Lidington, V. Leung, J. J. Boyle, S. S. Hamdulay,
P. C. Evans, D. O. Haskard, J. C. Mason, KLF2-dependent, shear stress-induced ex-
pression of CD59: A novel cytoprotective mechanism against complement-mediated
injury in the vasculature. J. Biol. Chem. 283, 14636–14644 (2008).
126. K. M. Parmar, H. B. Larman, G. Dai, Y. Zhang, E. T. Wang, S. N. Moorthy, J. R. Kratz,
Z. Lin, M. K. Jain, M. A. Gimbrone Jr., G. García-Cardeña, Integration of flow-dependent
endothelial phenotypes by Kruppel-like factor 2. J. Clin. Invest. 116, 49–58 (2006).
127. G. Pearson, J. M. English, M. A. White, M. H. Cobb, ERK5 and ERK2 cooperate to
regulate NF-kB and cell transformation. J. Biol. Chem. 276, 7927–7931 (2001).
128. K. Cude, Y. Wang, H.-J. Choi, S.-L. Hsuan, H. Zhang, C.-Y. Wang, Z. Xia, Regulation of
the G2–M cell cycle progression by the ERK5–NFkB signaling pathway. J. Cell Biol.
177, 253–264 (2007).
129. A. E. S. Simões, D. M. Pereira, S. E. Gomes, H. Brito, T. Carvalho, A. French, R. E. Castro,
C. J. Steer, S. N. Thibodeau, C. M. P. Rodrigues, P. M. Borralho, Aberrant MEK5/ERK5
signalling contributes to human colon cancer progression via NF-kB activation. Cell
Death Dis. 6, e1718 (2015).
Funding: This work was supported by the UCSF Department of Anesthesia, the National
Science Foundation Graduate Research Fellowship Program (#1144247), and the San Francisco
Foundation. The Gray laboratory acknowledges the support of the Linde Program in Chemical
Biology.Author contributions: K.W., F.X., A.P., and J.H. designed the research; K.W., F.X., K.F.,
A.T., S.K., S.S., and A.P. performed the research; J.W. and N.S.G. contributed new reagents and
analytic tools; K.W., F.X., K.F., and S.S. analyzed data; and K.W. and J.H. wrote the paper.
Competing interests: The authors declare that they have no competing interests.
Submitted 18 November 2014
Accepted 7 August 2015
Final Publication 25 August 2015
10.1126/scisignal.aaa3206
Citation: K. Wilhelmsen, F. Xu, K. Farrar, A. Tran, S. Khakpour, S. Sundar, A. Prakash,
J. Wang, N. S. Gray, J. Hellman, Extracellular signal–regulated kinase 5 promotes acute
cellular and systemic inflammation. Sci. Signal. 8, ra86 (2015)..SCIENCESIGNALING.org 25 August 2015 Vol 8 Issue 391 ra86 14
 (391), ra86. [doi: 10.1126/scisignal.aaa3206]8Science Signaling 
Nathanael S. Gray and Judith Hellman (August 25, 2015) 
Samira Khakpour, Shirin Sundar, Arun Prakash, Jinhua Wang, 
Kevin Wilhelmsen, Fengyun Xu, Katherine Farrar, Alphonso Tran,
and systemic inflammation
regulated kinase 5 promotes acute cellular−Extracellular signal
This information is current as of November 26, 2016. 
The following resources related to this article are available online at http://stke.sciencemag.org. 
Article Tools
http://stke.sciencemag.org/content/8/391/ra86
article tools: 
Visit the online version of this article to access the personalization and
Materials
Supplemental
http://stke.sciencemag.org/content/suppl/2015/08/21/8.391.ra86.DC1
"Supplementary Materials"
Related Content
http://stke.sciencemag.org/content/sigtrans/9/451/ec248.abstract
http://stke.sciencemag.org/content/sigtrans/9/443/ec201.abstract
http://science.sciencemag.org/content/sci/352/6289/aad7993.full
http://stke.sciencemag.org/content/sigtrans/9/430/ec131.abstract
http://stke.sciencemag.org/content/sigtrans/9/420/ec68.abstract
http://science.sciencemag.org/content/sci/351/6279/1333.full
http://stke.sciencemag.org/content/sigtrans/9/410/ec8.abstract
http://stm.sciencemag.org/content/scitransmed/6/233/233ec73.full
http://science.sciencemag.org/content/sci/347/6227/1201.full
http://stke.sciencemag.org/content/sigtrans/8/366/eg2.full
http://stke.sciencemag.org/content/sigtrans/7/349/ra102.full
's sites:ScienceThe editors suggest related resources on 
References
http://stke.sciencemag.org/content/8/391/ra86#BIBL
This article cites 128 articles, 59 of which you can access for free at: 
Permissions
http://www.sciencemag.org/about/permissions.dtl
Obtain information about reproducing this article: 
reserved. 
DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights
American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, 
 (ISSN 1937-9145) is published weekly, except the last December, by theScience Signaling
 o
n
 N
ovem
ber 26, 2016
http://stke.sciencem
ag.org/
D
ow
nloaded from
 
